These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 31795416)
1. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action. Chang WT; Lo YC; Gao ZH; Wu SN Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416 [TBL] [Abstract][Full Text] [Related]
2. Inhibitory Effective Perturbations of Cilobradine (DK-AH269), A Blocker of HCN Channels, on the Amplitude and Gating of Both Hyperpolarization-Activated Cation and Delayed-Rectifier Potassium Currents. Lu TL; Lu TJ; Wu SN Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244431 [TBL] [Abstract][Full Text] [Related]
3. Characterization of the Synergistic Inhibition of Liu PY; Chang WT; Wu SN Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138174 [TBL] [Abstract][Full Text] [Related]
4. Effects of Sesamin, the Major Furofuran Lignan of Sesame Oil, on the Amplitude and Gating of Voltage-Gated Na Kuo PC; Kao ZH; Lee SW; Wu SN Molecules; 2020 Jul; 25(13):. PubMed ID: 32635522 [TBL] [Abstract][Full Text] [Related]
5. Synergistic Inhibition of Delayed Rectifier K+ and Voltage-Gated Na+ Currents by Artemisinin in Pituitary Tumor (GH3) Cells. So EC; Wu SN; Wu PC; Chen HZ; Yang CJ Cell Physiol Biochem; 2017; 41(5):2053-2066. PubMed ID: 28456794 [TBL] [Abstract][Full Text] [Related]
6. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease. Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats. Beck J; Henschel C; Chou J; Lin A; Del Balzo U Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032 [TBL] [Abstract][Full Text] [Related]
9. Effective Perturbations of the Amplitude, Gating, and Hysteresis of Hsiao HT; Lu GL; Liu YC; Wu SN Membranes (Basel); 2021 Aug; 11(8):. PubMed ID: 34436399 [TBL] [Abstract][Full Text] [Related]
10. Evidence for Inhibitory Perturbations on the Amplitude, Gating, and Hysteresis of A-Type Potassium Current, Produced by Lacosamide, a Functionalized Amino Acid with Anticonvulsant Properties. Cho HY; Chuang TH; Wu SN Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163091 [TBL] [Abstract][Full Text] [Related]
11. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526 [TBL] [Abstract][Full Text] [Related]
12. Characterization of Effectiveness in Concerted So EC; Gao ZH; Ko SY; Wu SN Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948124 [TBL] [Abstract][Full Text] [Related]
14. The comprehensive electrophysiological study of curcuminoids on delayed-rectifier K Kuo PC; Yang CJ; Lee YC; Chen PC; Liu YC; Wu SN Eur J Pharmacol; 2018 Jan; 819():233-241. PubMed ID: 29225191 [TBL] [Abstract][Full Text] [Related]
15. The Evidence for Sparsentan-Mediated Inhibition of Chuang TH; Cho HY; Wu SN Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052766 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Columbianadin, a Bioactive Coumarin Derivative, in Perturbing Transient and Persistent Chang WT; Wu SN Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435511 [TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation. Miao AF; Liang JX; Yao L; Han JL; Zhou LJ Ren Fail; 2021 Dec; 43(1):803-810. PubMed ID: 33966598 [TBL] [Abstract][Full Text] [Related]
18. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo. Huang H; Wang X; Zhang X; Wang H; Jiang W Toxicol Lett; 2020 Oct; 331():112-121. PubMed ID: 32534005 [TBL] [Abstract][Full Text] [Related]
19. Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men. Mäkinen S; Sree S; Ala-Nisula T; Kultalahti H; Koivunen P; Koistinen HA Diabetologia; 2024 Sep; 67(9):1943-1954. PubMed ID: 38814443 [TBL] [Abstract][Full Text] [Related]
20. Effects of midazolam on ion currents and membrane potential in differentiated motor neuron-like NSC-34 and NG108-15 cells. So EC; Wu KC; Kao FC; Wu SN Eur J Pharmacol; 2014 Feb; 724():152-60. PubMed ID: 24374009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]